GleamWall
中文EN

BGLC BioNexus Gene Lab Corp

Services-Medical Laboratories · Nasdaq · SEC CIK 1737523 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.3%
TTM net income YoY-27.2%
TTM EPS YoY-130.3%
Revenue 3-yr CAGR-60.6%
Net income 3-yr CAGR—

Margins

Gross margin2.0%
Operating margin-461.1%
Net margin-463.1%
FCF margin20.5%
EBITDA margin-443.3%

Returns

ROE-40.7%
ROA-35.7%
ROIC (approx.)-37.8%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.01x
Current ratio3.74x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.05x
Accruals ratio-37.3%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$7.42M$9.51M
Cost of revenue$6.34M$8.22M
Gross profit$1.09M$1.29M
R&D expense$50,670$47,511
SG&A expense$1.54M$1.83M
Operating income-$2.97M-$1.57M
Pretax income-$2.98M-$1.59M
Income tax$0-$3,494
Net income-$2.98M-$1.60M
EBITDA-$2.85M-$1.47M
EPS (diluted)—-0.09
Weighted avg. shares (diluted)—17.82M
Balance sheet
Cash & equivalents$2.38M$2.89M
Receivables$505,885$1.38M
Inventory$676,703$1.39M
Current assets$5.37M$7.43M
PP&E, net$1.60M$1.52M
Total assets$9.25M$10.43M
Current liabilities$520,957$1.95M
Total liabilities$637,856$2.11M
Shareholders' equity$8.61M$8.32M
Shares outstanding2.42M1.80M
Cash flow statement
Operating cash flow-$1.84M-$2.09M
Capital expenditure$36,971$226,989
Free cash flow-$1.88M-$2.32M
Investing cash flow$944,751$418,202
Financing cash flow$298,841$3,975
Depreciation & amortization$111,873$104,160
Stock-based compensation$794,770$141,000

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.